priavoid.com
  • Home
  • About us
    • Overview
    • Strategy
    • Management
    • Supervisory Board
    • Scientific Advisory Board
    • History
  • Drug Development
    • Therapeutic Focus
    • Technology
    • Pipeline
  • Investors and Media
    • News
    • Events
    • Partnering
    • Archive
  • Contact us
    • Careers
Select Page

Prof. Willbold´s interview with PharmaVentures

November 14th, 2017

Learn more
Düsseldorf-Jülich Symposium on Neurodegenera7ve Diseases 2017 Bildquelle: Fotolia

Prof. Dieter Willbold talks with Summer Park of PharmaVentures at Biotech and Money Investival, London in 2017.

News & Events:

Dr. Dagmar Juergens will attend the annual AAIC online conference
Dr. Dagmar Juergens will attend the annual AAIC online conference

22. June 2021
Funding from The Michael J. Fox Foundation
Funding from The Michael J. Fox Foundation

24. February 2021
Priavoid closes financing round
Priavoid closes financing round

12. February 2021
Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie
Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie

11. February 2021
Alzheimer´s Research: Important Milestone for PRI-002
Alzheimer´s Research: Important Milestone for PRI-002

4. February 2021
Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board
Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board

9. December 2020
New CEO of Priavoid
New CEO of Priavoid

2. September 2020
Priavoid Headquarters at LSC Düsseldorf
Priavoid Headquarters at LSC Düsseldorf

6. March 2020
Seed Investment
Seed Investment

6. May 2019
Prof. Willbold´s interview with PharmaVentures
Prof. Willbold´s interview with PharmaVentures

23. January 2018
Clinical trial with PRI-002
Clinical trial with PRI-002

31. May 2017
  • Home
  • Investors and Media
  • Legal Notice
  • Privacy Policy
  • Contact us
Copyright © 2021 Priavoid GmbH